Recent advances in islet transplantation using highly purified islets and effective immunosuppression strategies have resulted in substantial improvement in achieving insulin independence in type 1 diabetes patients. However, there are side effects from long-term immunosuppression, and transplant rejection and/or the recurrence of autoimmune attack of the transplanted islets cannot be completely prevented, even with immunosuppressive treatment. Therefore, construction of a safe and functional bioartificial pancreas (BAP) that provides an adequate environment for islet cells may be an important approach to treat diabetic patients. Various types of BAP devices have been developed and examined in animals. In this review, I introduce the previous BAP studies and our approach of BAP development.
INTRODUCTION
ated with the increased number of diabetic patients has also been a threat to many countries. To overcome diabetes, it is necessary to broadly develop the following The International Diabetes Federation (IDF) has announced that the number of patients with diabetes in the issues: world totals at least 230 million, and that the incidence 1. to broaden people's knowledge of diabetes globally; rate is equivalent to 6% of the total adult population 2. to recognize the significant effect of diabetes on pa-(http://www.dm-net.co.jp/calendar/2006/09/004396.php).
tients, society, and the economy; Over the next 20 years, it is estimated that this will in-3. to prioritize diabetes issues in the healthcare and crease to 350 million. Diabetes has been regarded as the medical fields in every country; greatest medical issue of the 21st century. Type 1 diabe-4. to implement measures that achieve high economic tes is usually diagnosed in children and young adults, effectiveness to prevent complications from diabetes; and in this type of diabetes, the body does not produce 5. to study societal strategies for the prevention of diainsulin. Type 2 diabetes is the most common form of betes; diabetes. In type 2 diabetes, either the body does not 6. to emphasize measures to deal with diabetes among produce enough insulin or the cells ignore the insulin. children, pregnant women, and the elderly; Type 2 diabetes has been increasing significantly, but 7. to strengthen research into treatments. both types of diabetes have become prevalent. The increase in the incidence of diabetes has been a serious Therefore, this review article outlines the development of a bioartificial pancreas for diabetes treatment, issue, particularly in developing countries. Causes of this rapid increase include environmental factors, such which corresponds to the above-mentioned item 7. as excessive fat intake associated with dietary changes, PROBLEMS OF DIABETES lack of exercise, and delays in the development of an infrastructure for providing appropriate medical treat-Diabetes refers to a metabolic disorder characterized by chronic hyperglycemia and has two pathogenic mecha-ment. Furthermore, the increased medical cost associ-12 KOBAYASHI nisms. Type 1 diabetes occurs when the pancreatic beta the world, and favorable quality of life (QOL) of recipients has been reported. Conversely, in contrast to the cells that produce insulin are destroyed by autoimmunity, leading to a drastically insufficient amount of insu-success of this type of transplant treatment, the problem of a significant shortage of donor pancreases has actu-lin within the body. Type 2 diabetes occurs when the amount of insulin secretion decreases or when hepatic ally emerged. In addition, pancreatic islet transplantation requires the long-term use of immunosuppressive or muscular cells are unable to absorb glucose efficiently due to decreased insulin sensitivity. Among the patients agents, thereby leading to a risk of various complications (11, 24) . No solutions have yet been found for these with diabetes, approximately 90% have type 2 diabetes. Type 2 diabetes is characterized by insulin resistance, problems with clinical transplantation settings. Various studies have been conducted to solve these problems. which is seemingly derived from obesity and lack of exercise, as well as abnormal insulin secretion. Although
One is the development of a bioartificial pancreas. noninsulin dependent, as the stage progresses, if abnor-BIOARTIFICIAL PANCREAS (BAP) mal insulin secretion is observed, the effects of diet regimens and oral hypoglycemic agents thus prove to be BAP is a device that consists of encapsulating glucose-responsive insulin-secreting cells. Within a BAP insufficient, and insulin self-injection the becomes necessary. On the other hand, type 1 diabetes refers to the device, oxygen and nutrition are supplied to the insulinsecreting cells encapsulated by a semipermeable mem-most severe form of diabetes, wherein insulin secretion decreases because pancreatic beta cells are destroyed by brane that serves as a septum via the membrane. Then the cells secrete insulin in response to the glucose con-autoimmunity. In order to prevent diabetic ketoacidosis induced by type 1 diabetes and to sustain life, insulin centration. The aforementioned immunoisolation membrane is designed to permeate substances that are essen-self-injection becomes necessary. However, the current mainstream insulin treatment is unable to control blood tial for the cells' life, such as oxygen, nutrients, and glucose, but not to penetrate cells, antibodies, and com-glucose precisely, corresponding to biological changes. Furthermore, it cannot prevent the occurrence of hypo-plements that would evoke an immune reaction ( Fig. 1 ). By encapsulating xenogenic (e.g., swine) pancreatic is-glycemia shock, hyperglycemic attack, and the corresponding three major complications-diabetic nephrop-lets and insulin-secreting cell lines to block foreign proteins and viruses, it protects patients from infection, and athy, neuropathy, and retinopathy-as well as a lot of long-term severe complications derived from vascular it is thereby possible to solve the shortage of donors for pancreatic islet transplants that serves as a barrier against diseases. These diabetes-related diseases have been increasing as the incidence rate rises (41,42).
immunological defense from the host for xenogenic pancreatic islets and artificial allogenic cells. Even though RECENT PROGRESS islet transplantation is minimally invasive, complications IN DIABETES TREATMENT including intrahepatic hematoma, portal thrombosis, and hemorrhaging have been reported in a limited number As recent progress in diabetes treatment, it has been expected that pancreas/pancreatic islet transplantation of cases. BAP holds tremendous potential to solve such can be replaced with insulin treatment. Pancreas/pancreatic islet transplantation enables autoregulation of insulin secretion in accordance with subtle biological changes in blood glucose, which is an ideal treatment for diabetes. Pancreatic islet transplantation refers to a method of implanting pancreatic islets isolated from the pancreas to the recipient's liver through a portal vein. Comparing pancreas transplantation with pancreatic islet transplantation, the latter is regarded as more attractive as a treatment, as it does not require any complicated surgical techniques and is not accompanied by any complications due to the pancreatic exocrine tissue. In 2000, a study from the University of Alberta in Canada recognized insulin independence in all seven recipients of pancreatic islet transplants. Since this incidence, pancreatic islet transplantation has come to receive significant attention The BAP immunoisolation system is designed to permeate worldwide (37) . Since this announcement of the Edmonsubstances that are essential for the cells to survive and functon protocol, from 1999 to 2005, approximately 400 tion, such as oxygen, nutrients, and glucose, but not to penetrate cells, antibodies, and complements. cases of pancreatic islet transplants were conducted in diverse problems related to islet transplantation. There-create a septum. This type of device enables the regulation of substance permeability and glucose responsive-fore, there is no doubt that, to date, several studies for BAP development have been promoted throughout the ness by changing the coating time and materials. Favorable nutrition/oxygen supply and glucose responsiveness world.
can be expected due to the thinness of the septum of IMPLANTATION SITES FOR BAP microcapsule BAP. However, the microcapsule type BAP is fragile and could be easily broken under kinetic In islet transplantation, since the success of the group loads within the body. In addition, considering the large of Lacy in transplanting rodent pancreatic islets through surface area of each of microcapsule including islets, an the portal vein in 1973 (21), the method whereby panextremely large space is required for BAP implantation. creatic islets are implanted into the liver through the por-When any unexpected events occur after BAP implantatal vein has also been used in current human pancreatic tion, it would be extremely difficult to remove the BAP. islet transplants. There have been some reports on ani-Since Lim and Sun (29) reported in 1980 that a capsulemal studies regarding transplants of pancreatic islets to type BAP composed of alginate and poly-L-lysine achieved sites including intraperitoneal sites (6), renal subcapcontrol glucose levels in diabetic mice for about 2 sules (12), spleen (13) , and subcutaneous sites (20) . For weeks, several successful cases of BAP transplants have large animals, the results from the extrahepatic sites are been reported. There has been research on polymers not as significant as those from intrahepatic transplants such as alginate-Ba 2+ , agarose hydrogel, and alginate-Lthrough the portal vein. It has been reported that BAP lysine (18,28,45). Regarding alginate-Ba 2+ , as a result of can be favorably implanted in various sites including instudies in nonobese diabetic (NOD) mice, the efficacy traperitoneal, epididymis, intramuscular, subcutaneous, of both allogenenic and xenogenic islets as a cell source and other sites (9) . A recent study has indicated a favorof BAP has been reported. For example, BAP using alloable result of implantation of BAP in the intermuscular graft transplantation achieved blood glucose control for space by using a growth factor to induce prevasculizamore than 350 days in mice (10), while BAP with fetal tion around the BAP device (5).
porcine pancreatic islets controlled blood glucose levels TYPES OF BAP DEVICES for 140 days in mice (35) . For the BAP using agarose hydorogel capsules, blood glucose control has been ob-The types of devices for BAP have so far included served in allogenic mice for at least 100 days (23) . Howmicrocapsules, synthetic blood vessels, and macrocapever, for xenotransplants, it has been indicated that agarsules (Fig. 2) .
ose hydorogel capsules are unable to effectively trap Microcapsule Type BAP antibodies, complements, and cytokines, and so they cannot efficiently protect the encapsulated cells. It is es-The microcapsule type is intended to protect pancresential for the success of xenotransplants to overcome atic islets by coating them with various substances to the hyperacute rejection mediated by antibodies and compliments. To address the problem, a study was implemented aimed at immune isolation by mutual interference between the compliments and polyanion (17) . Consequently, a method of adding polystyrene sulfonic acid, which strongly interferes with compliments, into agarose hydorogel was adopted (44) . In clinical applications using human pancreatic islets, BAP utilizing alginate poly-L-lysine did not evoke any complications, and the patients became insulin independent up to 9 months later, thereby having improved QOL (38) . Regarding microcapsulated pancreatic islets, in 1997, AmCyte (USA) conducted clinical studies in New Zealand using capsulated porcine pancreatic islets (14) . In 2003, phase I/II clinical studies on intraperitoneal transplantation of capsulated human pancreatic islets were started in North America. connected to an arteriovenous shunt, and the insulin-secreting cells are cultivated in the septum within the glucose control was maintained for several months, but proliferation of fibroblasts around the device was histo-device. This type of BAP features favorable glucose responsiveness, because the blood flow passes through the logically found (3). Similar findings were observed in other animal species (1,2,15). In 1991, Lacy et al. re-sides of the septum. It also easily permeates oxygen, nutrients, etc., advantageously. On the other hand, be-ported a subcutaneous implantation of macrocapsule typed BAP (25) . Pancreatic islets were enclosed in a cause surgery is necessary to connect the device to the arterial vein, invasiveness increases in comparison with narrow tube with a thin membrane and approximately 60 days of blood glucose control was achieved in mice. other types of devices. In 1975, Chick, et al. reported an interesting blood perfusion type of BAP, wherein a de-This study clearly indicated that when pancreatic islets were injected indiscreetly, the implanted pancreatic is-vice composed of a bundle of hollow fibers was connected with an arteriovenous shunt to enable the cultiva-lets agglutinated, and necrosis thereby occurred from the center of the pancreatic islets, and glucose-responsive tion of pancreatic islet cells in the fibers (7) . Such a perfusion-type device using fine hollow fibers allowed insulin secretion decreased due to the increased size of pancreatic islets. As a result, long-term effects of trans-favorable glucose-responsive insulin secretion. However, it was reported that perfusion-type BAP devices planted islets were not obtained. In order to solve this problem, efforts have been were susceptible to embolism due to blood clot formation, resulting in difficulty in the long-term use of BAP made to maintain cell performance by encapsulating the transplanted pancreatic islets in alginate hydrogel to pre- (40, 43) . As an improved version, the same group conducted research on a device possessing coil-like hollow vent islets from encroaching upon each other and agglutinating. The results showed that proliferation of fibro-fibers with a diameter of 5-6 mm. When transplanting the BAP device into dogs, the concomitant use of exoge-blasts was observed in isolation membranes with small pores, whereas less proliferation of fibroblasts occurred nous insulin administration was still required, but more than 3 years of blood glucose level control has been around isolation membranes having relatively large pores and a smooth surface (27). It was also reported achieved in allogenic transplants (39) . In the case of xenotransplants in which the BAP devices were filled that the allotransplant experiment in dogs using an XM-50 membrane device achieved more than 60 days of with porcine pancreatic islets, the result was not as favorable as that from allotransplants, but blood glucose blood glucose control (26) . In the subcutaneous BAP transplant, less angiogenesis and resultant graft defi-levels were controlled for more than 8 months in dogs (31). This type of device obtained FDA approval in ciency were noted. It was reported that implanted pancreatic islets in the 1996, but it has not yet been in practical use. Multiple devices are necessary to achieve blood glucose control, device was improved after inducing angiogenesis (19) . Another report stated that 100 days of blood glucose and thus they increase the risk of clot formation.
Blood Perfusion Type BAP
control was achieved in diabetic mice by administering Macrocapsule Type BAP subcutaneous injection of basic fibroblast growth factors (bFGF) prior to BAP device implantation (36) . Intraperi-The macrocapsule type of BAP includes a diffusion chamber in which pancreatic islets are enclosed in a sac toneal transplants of mouse insulin-secreting MIN6 cells harboring sandwich-type BAP with a silicon ring septum composed of two septa and a cylinder-like capsule-type device. It is advantageous that this chamber can be eas-achieved 50 weeks of blood sugar control in diabetic rats (34) . ily implanted into an intraperitoneal or subcutaneous space and is also easy to remove. However, the macro-Various types of BAP devices have been studied, and the animal experiments have so far achieved only short-capsule-type BAP causes proliferation of fibroblasts on the surface of devices over time, resulting in the de-term success. crease in nutrient/oxygen supply to the pancreatic islets OUR STRATEGY FOR BAP DEVELOPMENT and metabolite diffusing capacity. In addition, it takes considerable time to induce new blood vessels. Further-
We are now developing a BAP device in collaboration with Kuraray Medical Inc. (Tokyo, Japan) by adopt-more, when injecting pancreatic islets into the device, the pancreatic islets agglutinate, which easily leads to ing a dialysis technique. We have focused on the use of polyethylene-vinyl alcohol (EVAL) membrane, which is cell necrosis. Therefore, its glucose responsiveness is inferior to that of the microcapsule type. In 1980, Archer based on studies of an insulin nonabsorptive property assay (16) . As shown in Figure 3 , it is important to de-et al. announced another type of BAP in which pancreas islets are enclosed in a narrow cylindrical tube. After sign the pore size of hollow fibers with consideration of blood cell sizes as well as molecular weights/sizes of enclosing mouse pancreatic islets in a tube composed of an Amicon XM-50 membrane, a transplant was con-the main important molecules and insulin. We also used unwoven polytetrafluoroethylene (PTFE) fabric in which ducted in streptozotocin-induced diabetic hamsters. Blood the surface was processed with polyamino urethane in development of a method for efficiently inducing differentiation of the stem cells to pancreatic beta cells and order to provide cells with an appropriate scaffold. We created an external whole blood perfusion type of BAP identification of pancreatic stem cells have not yet been achieved. We have assumed that one of the reasons for using porcine pancreatic islets as a cell source. In an experiment using a totally pancreatectomized pig model such difficulties is due to multipotency and active proliferative properties of such stem cells. While studies on of diabetes, favorable blood glucose control was observed for a week (16) . These external BAP devices are the utilization of porcine islets have progressed, the problem of zoonosis, biocompatibility between humans suitable for use in the intensive care unit (ICU) after invasive surgery for diabetic patients. However, when and pigs, and ethical issues has emerged. Study on transduction of an insulin gene into the body of animals or subjected to a chronic illness of diabetes, it is not appropriate in terms of the patients' QOL. Therefore, it is previously established cells in order to enhance insulin secretion has been conducted, but there is a risk of in-important to develop an implant bag-type BAP. Currently, we are seeking to design and develop a subcuta-ducing hypoglycemia due to excessive uncontrolled insulin secretion. To address these problems, we have neously implantable BAP device. Considering the ease of device removal, it is preferable to implant a BAP de-made great efforts to generate a tightly regulated functional human hepatic and pancreatic beta cell lines using vice subcutaneously. However, because subcutaneous areas lack adequate blood flow for a BAP device, it is a currently available gene transfer technology and cell culture system (22,33). critically essential to induce sufficient new blood vessels around the implanted device. We have therefore focused REFERENCES on bFGF for its strong capacity for angiogenesis. By secreting cells (4,8,30) has been indicated. However, the
